NVAX

Novavax’s early 2024 performance was strong, with a 36% return including dividends. Recent challenges include a revenue decline, a new licensing model, and mixed analyst targets.

Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and their stock prices) often stay small because their subscale operations make it harder to expand their competitive moats.

At $9.99, investors question whether Novavax’s price reflects its sales base, especially after a 93.4% drop over five years.

Biogen (BIIB) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.

Moderna shares fell 18% after reports that personalized melanoma vaccine data leaked online before Phase 3 results.

The market saw the Dow jump over 500 points while DBV Technologies shares slid.

Novavax (NVAX) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

Over the past six months, Novavax has been a great trade, beating the S&P 500 by 17.7%. Its stock price has climbed to $10.87, representing a healthy 25.4% increase. This was partly due to its solid quarterly results, and the performance may have investors wondering how to approach the situation.